Andreas Windemuth
Overview
Explore the profile of Andreas Windemuth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugiyama M, Cui H, Redka D, Karimzadeh M, Rujas E, Maan H, et al.
Sci Rep
. 2021 Dec;
11(1):23315.
PMID: 34857794
The COVID-19 pandemic has highlighted the urgent need for the identification of new antiviral drug therapies for a variety of diseases. COVID-19 is caused by infection with the human coronavirus...
2.
MacKinnon S, Madani Tonekaboni S, Windemuth A
Curr Protoc
. 2021 Nov;
1(11):e302.
PMID: 34794211
Drug-Target interaction predictions are an important cornerstone of computer-aided drug discovery. While predictive methods around individual targets have a long history, the application of proteome-scale models is relatively recent. In...
3.
Lizano P, Lutz O, Ling G, Padmanabhan J, Tandon N, Sweeney J, et al.
Transl Psychiatry
. 2018 Oct;
8(1):215.
PMID: 30310054
Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging...
4.
Ruano G, Makowski G, Windemuth A, Kocherla M, Weiss S, Goethe J, et al.
Per Med
. 2018 May;
3(2):131-137.
PMID: 29793288
Many drugs are metabolized by highly polymorphic cytochrome P450 (CYP) enzymes. Among these enzymes, members of the CYP2 family coded by the CYP2D6, CYP2C9 and CYP2C19 genes are best amenable...
5.
Holford T, Windemuth A, Ruano G
Per Med
. 2018 May;
2(3):239-249.
PMID: 29793267
No abstract available.
6.
Ruano G, Villagra D, Rahim U, Windemuth A, Kocherla M, Bower B, et al.
Per Med
. 2018 May;
5(6):579-587.
PMID: 29788619
Objective: This study compared the types and carrier prevalences of clinically significant DNA polymorphisms in the cytochrome P450 (CYP450) genes CYP2C9, CYP2C19 and CYP2D6 in major depressive disorder patients with...
7.
Ruano G, Thompson P, Villagra D, Bower B, Kocherla M, Yazdanpanah G, et al.
Per Med
. 2018 May;
5(3):225-232.
PMID: 29783498
Background: Polymorphisms in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes significantly alter the effective warfarin dose. The CYP2C9*2 (430C>T), CYP2C9*3 (1075A>C) and...
8.
Molinski S, Shahani V, Subramanian A, MacKinnon S, Woollard G, Laforet M, et al.
Proteins
. 2018 Mar;
86(8):833-843.
PMID: 29569753
Cystic Fibrosis (CF) is caused by mutations in the CFTR gene, of which over 2000 have been reported to date. Mutations have yet to be analyzed in aggregate to assess...
9.
Somody J, MacKinnon S, Windemuth A
Drug Discov Today
. 2017 Aug;
22(12):1792-1799.
PMID: 28843631
Structure-based computational drug discovery efforts have traditionally focused on the structure of a single, well-known drug target. Important applications, such as target deconvolution and the analysis of polypharmacology, require proteome-scale...
10.
Molinski S, Shahani V, MacKinnon S, Morayniss L, Laforet M, Woollard G, et al.
Biochem Biophys Res Commun
. 2016 Dec;
483(1):502-508.
PMID: 28007597
The investigational compound BIA 10-2474, designed as a long-acting and reversible inhibitor of fatty acid amide hydrolase for the treatment of neuropathic pain, led to the death of one participant...